Company Profile

LifePharms LLC
Profile last edited on: 7/22/2021      CAGE: 4AZG7      UEI:

Business Identifier: Natural Product Drug Development
Year Founded
2006
First Award
2001
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

143 Shaw Street
New London, CT 06320
   (860) 405-9219
   info@lifepharms.com
   www.lifepharms.com
Location: Single
Congr. District: 02
County: New London

Public Profile

LifePharms, Inc. is a biotechnology company working on new, untapped source of fungal extracts for drug discovery, agrochemical, enzyme, and food science research. The firm's field collection of North American basidiomycetes and ascomycetes (mushrooms) contain countless chemically diverse and unique compounds, with none of the fungus coming from fungal cultures. Instead, all samples have all been picked in the wild and identified by mycologists before being turned into fungal extracts in laboratories. Natural products have consistently been the most successful source of drug leads. Between 1983 and 1994, 39% of antibacterial and anticancer drugs were derived from natural products. Also, in that same time period, 39% of all new approved drugs were from either natural products or derived from natural products.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 2 NIH $1,818,050
Project Title: Hsp90 Inhibitors to Combat Antifungal Drug Resistance.
2012 1 NIH $587,757
Project Title: Novel Antibacterial Scaffold From Natural Products
2011 1 NIH $300,000
Project Title: Novel Antifungals For Immunocompromised/Hiv Patients.
2010 1 NIH $211,698
Project Title: Nucleoside Hydrolase Inhibitors From Natural Products For Leishmania
2010 1 NIH $300,000
Project Title: Discovery of Novel Agents Against M. Tuberculosis

Key People / Management

  Esteban Edward Mena -- President and Chief Scientific Officer

  Wendy P Login -- VP, Director of Business Development

  Robert A Volkmann -- Director of Chemistry

Company News

There are no news available.